Cytidine diphosphate diacylglycerol (CDP-DAG) is the activated form of phosphatidic acid and the branch-point intermediate of glycerophospholipid metabolism — the gateway through which cells build phosphatidylinositol and cardiolipin.
CDP-DAG is phosphatidic acid bearing a cytidine diphosphate headgroup, made in the reversible reaction joining CTP with phosphatidate and releasing pyrophosphate; the catalyst, phosphatidate cytidylyltransferase, is a membrane-bound nucleotidyltransferase (EC 2.7.7.41).
It is not a bulk membrane constituent but a short-lived branch-point intermediate in both prokaryotic and eukaryotic organisms.
Biosynthesis & Metabolism
Two unrelated enzyme families make it: the integral-membrane CDS enzymes, products of the CDS1 and CDS2 genes on the endoplasmic reticulum (CDS2 the suggested major supplier), and TAMM41, a peripheral protein of the inner mitochondrial membrane feeding cardiolipin synthesis.
On the ER, phosphatidylinositol synthase condenses CDP-DAG with inositol and releases CMP — the final step of a pathway limited to the ER.
In mitochondria, PGP synthase converts CDP-DAG to phosphatidylglycerol phosphate, dephosphorylation gives phosphatidylglycerol, and cardiolipin synthase joins one more CDP-DAG with phosphatidylglycerol to finish cardiolipin.
Physiological Role
CDP-DAG supply sets phosphatidylinositol availability: PI is phosphorylated to PI(4,5)P2, which phospholipase C cleaves into the second messengers inositol trisphosphate and diacylglycerol — the heart of inositol phosphate signaling.
During phospholipase C signaling, CDS enzymes catalyze the rate-limiting step of PI resynthesis, keeping phosphoinositide pools — which also steer membrane traffic and the actin cytoskeleton — from collapsing.
Toward mitochondria it sustains cardiolipin, the signature lipid of that organelle, required for cristae morphology, fission and fusion, and electron transport chain supercomplexes.
The cardiolipin branch depends on phosphatidylcholine: the remodeling enzyme tafazzin transfers linoleic acid from PC to monolysocardiolipin.
Clinical Relevance
Barth syndrome follows mutations in tafazzin, an enzyme of cardiolipin biosynthesis, leaving cardiolipin remodeling insufficient.
CDS expression is regulated by transcription factors, and CDS enzymes may also serve mitochondrial cardiolipin synthesis, tying CDP-DAG flux to bioenergetics.
Dysregulated phosphoinositide species such as PIP3 matter in cancer biology, placing CDP-DAG availability upstream of oncogenic signaling.